Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (GB:0HFR)
:0HFR
0HFR Stock Chart & Stats
$7.66
-$2.01(-14.41%)
At close: 4:00 PM EST
$7.66
-$2.01(-14.41%)
Day’s Range― - ―
52-Week Range$7.23 - $14.45
Previous CloseN/A
Volume26.29K
Average Volume (3M)6.77K
Market Cap
$641.63M
Enterprise Value$686.05M
Total Cash (Recent Filing)$101.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Dec 22, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding85,893,840
10 Day Avg. Volume6,245
30 Day Avg. Volume6,774
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.63
Forecast
1Y Price Target
$42.00Price Target Upside448.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Alzheimer's Therapy EfficacyLong-term benefits of oral blarcamesine therapy in patients with Alzheimer's disease underscore potential value.
Market Expansion PotentialPossible blarcamesine EU market entry next year with a potential regulatory decision on the Marketing Authorization Application soon.
Schizophrenia Treatment DevelopmentAnavex recently reported positive top-line results from its placebo-controlled Phase 2 study evaluating ANAVEX3-71 for treatment of schizophrenia in adults on stable antipsychotic medication.
Bears Say
Bearish Market SentimentThe short percentage of float has held steady at approximately 30% for over 6 months, indicating significant bearish sentiment in the market.
Financial PerformanceThe F3Q25 net loss of $13.2M, or $0.16 per share, was moderately wider than the forecast for a net loss of $0.13 per share.
Regulatory UncertaintyPhase 2b/3 and open-label extension data are confusing due to Covid disruptions, leading to uncertainty if the cohort size is large enough to receive full approval.
Anavex Life Sciences News
0HFR FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest share price was $7.23 and its highest was $14.45 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $641.63M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Dec 22, 2025 which is in 46 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Aug 12, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.018.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.15.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 85,893,840 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -3.797%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in GB:0HFR
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.00 (448.30% Upside)
$42.00 (448.30% Upside)
Blogger Sentiment
Bullish
GB:0HFR Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.32%
12-Months-Change
Fundamentals
Return on Equity
-43.63%
Trailing 12-Months
Asset Growth
-27.67%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
0HFR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with strong ongoing development and financial health, but also challenges in administrative costs and net losses. The company's advancements in Alzheimer's treatment and cash flow are positive, but operational costs and delays in Parkinson's study present concerns.View all GB:0HFR earnings summaries0HFR Stock 12 Month Forecast
Average Price Target
$42.00
▲(448.30% Upside)
Technical Analysis
Vir Biotechnology
―
Nurix Therapeutics
―
AbCellera Biologics
―
Day One Biopharmaceuticals
―
Bicara Therapeutics Inc.
―
Options Prices
Currently, No data available
---